Leap Therapeutics Inc (NASDAQ:LPTX)’s Trend Unknown, Especially After Increased Shorts

June 1, 2018 - By Vivian Park

The stock of Leap Therapeutics Inc (NASDAQ:LPTX) registered an increase of 1.73% in short interest. LPTX’s total short interest was 123,200 shares in June as published by FINRA. Its up 1.73% from 121,100 shares, reported previously. With 140,700 shares average volume, it will take short sellers 1 days to cover their LPTX’s short positions. The short interest to Leap Therapeutics Inc’s float is 3.14%.

The stock increased 11.91% or $0.99 during the last trading session, reaching $9.3. About 152,408 shares traded or 17.79% up from the average. Leap Therapeutics, Inc. (NASDAQ:LPTX) has risen 22.88% since June 1, 2017 and is uptrending. It has outperformed by 10.31% the S&P500.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapeutics in cancer biology. The company has market cap of $136.72 million. The Company’s clinical stage programs include DKN-01, a monoclonal antibody targeting Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric and biliary tract cancers, as well as in Phase I clinical trial in patients with non-small cell lung cancer; and TRX518, a monoclonal antibody that is in Phase I clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. It currently has negative earnings. Leap Therapeutics, Inc. has a clinical trial collaboration agreement with Merck & Co., Inc. to investigate LeapÂ’s DKK1 antagonist, DKN-01, in combination with MerckÂ’s anti-PD-1 therapy, KEYTRUDA, in patients with relapsed or refractory advanced esophagogastric cancers.

More news for Leap Therapeutics, Inc. (NASDAQ:LPTX) were recently published by: Benzinga.com, which released: “58 Biggest Movers From Yesterday” on June 01, 2018. Globenewswire.com‘s article titled: “Leap Therapeutics Reports First Quarter 2018 Financial Results” and published on May 11, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.